Research Nester recently published report titled “Global Human Respiratory Syncytial Virus Treatment Market: Demand Analysis & Opportunity Outlook 2027” delivers detailed overview of the global human respiratory syncytial virus treatment market on the basis of route of administration, distribution channel, and region.
Based on route of administration, the global human respiratory syncytial virus treatment market is bifurcated into oral and parenteral form; and by distribution channel the market is segmented into retail and hospital pharmacies.
The global human respiratory syncytial virus treatment market is anticipated to project a CAGR of more than 12%, during the forecast period (2019-2027).
The market is expected to show a noteworthy growth in the upcoming years on account of RSV being a major cause of respiratory diseases globally. Moreover, the development of drugs and vaccines with better effectiveness and limited drug toxicity is also anticipated to propel the growth of the market during the forecast year. Furthermore, increased understanding of RSV biology for the development of drugs and vaccines to cure, treat, and prevent the infection owing to advancements in technology is projected to drive the market growth.
Based on region, the global human respiratory syncytial virus treatment market is segmented into five major regions including North America, Europe, Asia Pacific, Latin America, and the Middle East & Africa.
The market in North America is expected to show a significant growth owing to increased prevalence of viral infection among infants in this region. The market in Asia Pacific is also anticipated to show a considerable growth on the back of high population density and rising incidences of infections in this region.
Increased Prevalence of Respiratory Syncytial Virus
Respiratory syncytial virus is among the leading causes of lower respiratory tract infections in infants and young children. This can be attributed to less therapeutic options available to prevent or treat the disease, which is expected to propel the growth of the market. According to the Centers for Disease Control and Prevention (CDC), in the US there is an average of 1.5 million infant outpatient visits, out of which, around 57,000 are hospitalized every year, due to RSV infection.
However, the absence of safe and effective antiviral drugs along with high prices of monoclonal antibodies are expected to operate as key restraints to the growth of global human respiratory syncytial virus treatment market over the forecast period.
Further, for the in-depth analysis, the report encompasses the industry growth drivers, restraints, supply and demand risks, market attractiveness, BPS analysis and Porter’s five force model.
This report also provides the existing competitive scenario of some of the key players of the global human respiratory syncytial virus treatment market which includes company profiling of F. Hoffmann-La Roche Ltd., AstraZeneca, Merck & Co., Inc., AbbVie, Inc., GlaxoSmithKline plc., ReViral Ltd, Gilead Sciences, Inc. , Teva Pharmaceutical Industries Ltd., and other prominent players .The profiling enfolds key information of the companies which encompasses business overview, products and services, key financials and recent news and developments. As a whole, the report depicts detailed overview of the global human respiratory syncytial virus treatment market that will help industry consultants, equipment manufacturers, existing players searching for expansion opportunities, new players searching possibilities and other stakeholders to align their market centric strategies according to the ongoing and expected trends in the future.